NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Marex Group plc, commonly referred to as Marex, a diversified global financial services platform, has officially announced the pricing details for its public offering of 10,283,802 ordinary shares. This offering is being conducted by certain selling shareholders, who are collectively termed the Selling Shareholders. Each share in this offering is priced at $35.50. In an added dimension, the Selling Shareholders have granted underwriters a 30-day option to purchase up to an additional 1,542,570 ordinary shares, which can provide further liquidity and flexibility in the market.

Importantly, Marex will not be selling any ordinary shares in this offering; consequently, the company will not receive any proceeds from the sale of shares by the Selling Shareholders. The public offering is anticipated to close today, April 17, 2025, contingent upon the fulfillment of customary closing conditions.

The underwriting for this offering is being managed by some of the most reputable names in the financial services industry. Goldman Sachs & Co. LLC, Barclays, and Jefferies are acting as the lead book-running managers, while also serving as representatives of the underwriters for the offering. Additional bookrunners include UBS Investment Bank, Keefe, Bruyette & Woods, a Stifel Company, Piper Sandler & Co., TD Securities, and Berenberg.

For those interested in participating in the offering, it is essential to note that the offering is made solely through a prospectus. Copies of the prospectus related to this public offering can be obtained from the following contacts:

  • Goldman Sachs & Co. LLC
    Attention: Prospectus Department
    200 West Street, New York, New York 10282
    Phone: 1-866-471-2526
    Email: prospectus-ny@ny.email.gs.com
  • Barclays Capital Inc.
    c/o Broadridge Financial Solutions
    1155 Long Island Avenue, Edgewood, NY 11717
    Phone: 1-888-603-5847
    Email: barclaysprospectus@broadridge.com
  • Jefferies LLC
    Attention: Equity Syndicate Prospectus Department
    520 Madison Avenue, New York, NY 10022
    Phone: (877) 821-7388
    Email: Prospectus_Department@Jefferies.com

A registration statement on Form F-1 related to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). It is important to clarify that this press release should not be interpreted as an offer to sell or a solicitation of an offer to buy any securities, nor should it be construed as an offer, solicitation, or sale in any jurisdiction where such actions would be unlawful prior to registration or qualification under securities laws.

Forward Looking Statements
This release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements do not pertain to historical facts and should be recognized as projections regarding future events, including expected closing dates of the offering. Terms such as may, will, expect, anticipate, aim, estimate, intend, plan, believe, potential, and similar expressions identify these forward-looking statements. However, these statements carry inherent risks and uncertainties that may cause actual outcomes to differ significantly from anticipated results.

Various factors could affect the performance of Marex, including subdued commodity market activity, geopolitical tensions, and changes in interest rates. Furthermore, the risks related to clients defaulting on financial obligations, regulatory challenges, data security issues, and compliance with laws and regulations are factors that could materially impact the company's operations and financial condition.

For more detailed information about potential risks and uncertainties, stakeholders are encouraged to reference the Risk Factors section contained in Marex's Registration Statement filed on Form F-1 with the SEC on April 14, 2025, alongside other relevant reports filed with the SEC.

The forward-looking statements in this announcement are limited to the date on which they are made. Unless mandated by law, Marex does not undertake any obligation to update or revise these statements in light of new information or unexpected events occurring after the announcement date.

For further inquiries, please contact:

Nicola Ratchford / Adam Strachan
Marex
Phone: +44 (0) 778 654 8889 / +1 914 200 2508
Email: nratchford@marex.com / astrachan@marex.com